biopharmaceut    biopharmaceut from wikipedia free encyclopedia jump navig jump search biopharmaceut biolog al medic product biolog biolog pharmaceut drug product manufactur extract semisynthes biolog sourc differ total synthes pharmaceut includ vaccin blood blood compon allergen somat cell gene therapi tissu recombin therapeut protein live cell cell therapi biolog compos sugar protein nucleic acid complex combin substanc live cell tissu they precursor compon isol live sourc human anim plant fungal microbi terminolog surround biopharmaceut vari group entiti term refer subset therapeut gener biopharmaceut categori some regulatori agenc term biolog medicin product therapeut biolog product refer engin macromolecular product protein nucleic acid base drug distinguish product blood blood compon vaccin extract directli biolog sourc specialti drug classif pharmaceut high cost drug biolog the european medicin agenc term advanc therapi medicin product atmp medicin human base gene cell tissu engin includ gene therapi medicin somat cell therapi medicin tissu engin medicin combin within ema context term advanc therapi refer atmp term nonspecif context gene base cellular biolog exampl forefront biomed treat varieti medic condit treatment 10 In jurisdict biolog regul pathway small molecul drug medic devic 11 the term biopharmacolog describ branch pharmacolog studi biopharmaceut    content   major class  1.1 extract live system 1.2 produc recombin dna 1.3 vaccin 1.4 gene therapi   biosimilar commerci larg scale product  4.1 transgen   regul  5.1 european union 5.2 unit state   see refer extern link    major class edit     blood plasma type biopharmaceut directli extract live system   extract live system edit some oldest form biolog extract bodi anim human import biolog includ  whole blood blood compon organ tissu transplant stem cell therapi antibodi passiv immun treat viru infect human breast milk fecal microbiota human reproduct cell  some biolog extract anim insulin commonli produc recombin dna produc recombin dna edit see biolog immunosuppress As indic term biolog refer wide rang biolog product medicin howev case term biolog restrict class therapeut approv develop produc biolog process involv recombin dna technolog these medic three type  substanc ident bodi key signal protein exampl blood product stimul protein erythropoetin growth stimul hormon name simpli growth hormon biosynthet human insulin analogu monoclon antibodi these antibodi human immun system fight bacteria virus custom design hybridoma technolog method counteract block substanc bodi target specif cell type exampl monoclon antibodi diseas tabl receptor construct fusion protein base natur occur receptor link immunoglobulin frame In case receptor construct detail specif immunoglobulin structur impart stabil featur term pharmacolog some exampl list tabl  biolog class medic narrow sens profound impact medic field rheumatolog oncolog cardiolog dermatolog gastroenterolog neurolog In disciplin biolog major therapeut option treatment diseas includ effect therapi exist therapi clearli inadequ howev advent biolog therapeut rais complex regulatori issu pharmacoeconom concern cost biolog therapi dramat higher convent pharmacolog medic thi factor relev biolog medic treatment chronic diseas rheumatoid arthriti inflammatori bowel diseas treatment untreat cancer remaind life the cost treatment typic monoclon antibodi therapi common indic gener rang 000 14 000 patient year older patient receiv biolog therapi diseas rheumatoid arthriti psoriat arthriti ankylos spondyl increas risk life threaten infect advers cardiovascular event malign 12 the substanc approv therapeut biosynthet human insulin recombin dna sometim refer rhi trade humulin develop genentech licens eli lilli compani manufactur market start 1982 major kind biopharmaceut includ  blood factor factor viii factor IX thrombolyt agent tissu plasminogen activ hormon insulin glucagon growth hormon gonadotrophin haematopoiet growth factor erythropoietin coloni stimul factor interferon interferon interleukin base product interleukin vaccin hepat surfac antigen monoclon antibodi variou addit product tumour necrosi factor therapeut enzym  research develop invest medicin biopharmaceut industri stood 65.2 billion 2008 13 exampl biolog recombin dna technolog includ   usan inn trade indic technolog mechan action   abatacept orencia rheumatoid arthriti immunoglobin ctla fusion protein cell deactiv   adalimumab humira rheumatoid arthriti ankylos spondyl psoriat arthriti psoriasi ulcer coliti crohn diseas monoclon antibodi tnf antagonist   alefacept amev chronic plaqu psoriasi immunoglobin G1 fusion protein incomplet character   erythropoietin epogen anemia aris cancer chemotherapi chronic renal failur recombin protein stimul red blood cell product   etanercept enbrel rheumatoid arthriti ankylos spondyl psoriat arthriti psoriasi recombin human tnf receptor fusion protein tnf antagonist   infliximab remicad rheumatoid arthriti ankylos spondyl psoriat arthriti psoriasi ulcer colitu crohn diseas monoclon antibodi tnf antagonist   trastuzumab herceptin breast cancer human monoclon antibodi her2 neu erbb2 antagonist   ustekinumab stelara psoriasi human monoclon antibodi IL 12 IL 23 antagonist   denileukin diftitox ontak cutan cell lymphoma ctcl diphtheria toxin engin protein combin interleukin diphtheria toxin interleukin receptor binder   golimumab simponi rheumatoid arthriti psoriat arthriti ankylos spondyl ulcer coliti monoclon antibodi tnf antagonist   vaccin edit main articl vaccin mani vaccin grown tissu cultur gene therapi edit viral gene therapi involv artifici manipul viru includ desir piec genet materi biosimilar edit main articl biosimilar with expir numer patent blockbust biolog 2012 2019 interest biosimilar product follow biolog increas 14 compar small molecul consist chemic ident activ ingredi biolog vastli complex consist multitud subspeci due heterogen high process sensit origin follow biosimilar will exhibit variabl specif variant time safeti clinic perform origin biosimilar biopharmaceut remain equival lifecycl 15 16 process variat monitor modern analyt tool liquid chromatographi immunoassay mass spectrometri describ uniqu design space biolog thu biosimilar requir regulatori framework compar small molecul gener legisl 21st centuri address recogn intermedi ground test biosimilar the file pathway requir test small molecul gener test regist complet therapeut 17 In 2003 european medicin agenc introduc adapt pathway biosimilar term biolog medicin product thi pathway base thorough demonstr compar product exist approv product 18 within unit state patient protect afford care act 2010 creat abbrevi approv pathway biolog product biosimilar interchang fda licens refer biolog product 17 19 major hope link introduct biosimilar reduct cost patient healthcar system 14 commerci edit when biopharmaceut develop compani will typic appli patent grant exclus manufactur right thi primari develop drug recov invest cost develop biopharmaceut the patent law unit state europ differ requir patent european requir perceiv difficult satisfi the total number patent grant biopharmaceut risen 1970 In 1978 total patent grant 30 thi climb 15 600 1995 2001 34 527 patent applic 20 In 2012 US highest IP intellectu properti gener biopharmaceut industri gener 37 percent total number grant patent worldwid larg margin growth innov industri revis current IP system ensur greater reliabl develop invest promin topic debat US well 21 blood product human deriv biolog breast milk highli regul hard access market custom gener face suppli shortag product natur institut hous biolog design bank distribut product custom effect 22 convers bank reproduct cell widespread eas spermatozoa egg cell fertil treatment 23 larg scale product edit biopharmaceut produc microbi cell recombin coli yeast cultur mammalian cell line cell cultur plant cell cultur plant tissu cultur moss plant bioreactor configur includ photo bioreactor 24 import issu concern cost product low volum high puriti product desir microbi contamin bacteria virus mycoplasma altern platform product test includ plant plant pharmaceut transgen edit main articl pharm genet controversi method produc biopharmaceut involv transgen organ plant anim genet modifi produc drug thi product risk investor product failur scrutini regulatori bodi base perceiv risk ethic issu biopharmaceut crop repres risk cross contamin engin crop crop engin medic purpos one potenti approach technolog creation transgen mammal produc biopharmaceut milk blood urin onc anim produc typic pronuclear microinject method efficaci clone technolog creat addit offspr carri favor modifi genom 25 the drug manufactur milk genet modifi goat atryn market permiss block european medicin agenc februari 2006 26 thi decis revers june 2006 approv august 2006 27 regul edit european union edit In european union biolog medicin product 28 activ substanc produc extract biolog live system requir addit physico chemic test biolog test full characteris the characteris biolog medicin product combin test activ substanc final medicin product product process control for exampl  product process deriv biotechnolog technolog It prepar convent techniqu case blood plasma deriv product number vaccin activ substanc consist entir microorgan mammalian cell nucleic acid proteinac polysaccharid compon origin microbi anim human plant sourc mode action therapeut immunolog medicin product gene transfer materi cell therapi materi  unit state edit In unit state biolog licens biolog licens applic bla submit regul fda center biolog evalu research cber drug regul center drug evalu research approv requir year clinic trial includ trial human volunt even drug releas will monitor perform safeti risk the manufactur process satisfi fda good manufactur practic typic manufactur clean room environ strict limit amount airborn particl microbi contamin alter efficaci drug 29 see edit  antibodi drug conjug genet engin list recombin protein list pharmaceut compani nanobiopharmaceut  refer edit   definit biolog oxford dictionari rader RA juli 2008 Re defin biopharmaceut natur biotechnolog 26 743 51 doi 10.1038 nbt0708 743 pmid 18612293 drug fda glossari term food drug administr feb 2012 retriev april 2014 walsh 2003 biopharmaceut biochemistri biotechnolog second edit john wiley son ltd isbn 978 470 84326 gleason PP alexand GC starner CI ritter ST van houten HK gunderson BW shah ND septemb 2013 health plan util cost specialti drug chronic condit journal manag care pharmaci 19 542 doi 10.18553 jmcp.2013 19.7 542 pmid 23964615 thoma kate pollack andrew 15 juli 2015 specialti pharmaci prolifer along with question sink spring Pa new york time retriev octob 2015 murphi CO specialti pharmaci manag care strategi pdf retriev 24 septemb 2015 european medicin agenc tooltip definit advanc therapi medicin product committe advanc therapi cat retriev 2017 05 15 european medicin agenc advanc therapi medicin product retriev 2017 05 15 center biolog evalu research 2010 04 01 what biolog product food drug administr retriev 2014 02 09 unit state food drug administr august 2008 supplement applic propos label chang approv drug biolog medic devic final rule pdf feder regist 73 164 49603 10 pmid 18958946 kerr LD 2010 the biolog agent geriatr popul musculoskel med 27 175 180 briskfox financi biopharmaceut sector see rise despit credit crunch find analysi retriev 2009 03 11 calo fern ndez mart nez hurtado JL decemb 2012 biosimilar compani strategi captur biolog market pharmaceut 12 1393 408 doi 10.3390 ph5121393 pmc 3816668 pmid 24281342 schiestl stangler torella cepeljnik toll grau april 2011 accept chang qualiti attribut glycosyl biopharmaceut natur biotechnolog 29 310 doi 10.1038 nbt.1839 pmid 21478841 lamanna WC holzmann cohen HP guo schweigler stangler seidl schiestl april 2018 maintain consist qualiti clinic perform biopharmaceut expert opinion biolog therapi 18 369 379 doi 10.1080 14712598.2018 1421169 pmid 29285958 nick 2012 the US biosimilar act challeng face regulatori approv pharm med 26 145 152 doi 10.1007 bf03262388 ema 2008 10 30 question answer biosimilar medicin biolog medicin product pdf european medicin agenc retriev 2014 10 11 75 FR 61497 unit state food drug administr 2010 10 05 approv pathway biosimilar interchang biolog product pdf public hear request comment foster luke patent biopharmaceut industri compar US europ archiv origin 2006 03 16 retriev 2006 06 23 growth polici behind biopharmaceut innov phrma org phrma retriev 11 april 2018 carlyl erin the guy who trade your blood for profit retriev 2016 09 29 sperm donor australia donat sperm spermdonorsaustralia au retriev 2016 09 29 decker EL reski januari 2008 current achiev product complex biopharmaceut moss bioreactor bioprocess biosystem engin 31 doi 10.1007 s00449 007 0151 pmid 17701058 dove octob 2000 milk genom profit natur biotechnolog 18 10 1045 doi 10.1038 80231 pmid 11017040 phillip jone european regul curdl plan goat milk human antithrombin retriev 2006 06 23 Go ahead pharm goat drug bbc new 2006 06 02 retriev 2006 10 25 the commiss european commun 2003 06 25 commiss direct 2003 63 EC amend direct 2001 83 EC european parliament council commun code relat medicin product human pdf offici journal european union 159 62 kingham klasa carver 2014 key regulatori guidelin develop biolog unit state europ pdf john wiley son inc 75 88 retriev 11 april 2018   extern link edit  biolog product US nation librari medicin medic subject head mesh debbi strickland 2007 guid biotechnolog pdf biotechnolog industri organ bio retriev 2007 12 17 timothi coan ron elli 2001 06 01 report usa specialti pharmaceut gener biolog the next frontier pdf consum project technolog retriev 2007 12 17 about biolog nation psoriasi foundat 2006 11 01 retriev 2007 12 17       retriev http en wikipedia org php titl biopharmaceut oldid 843686388 categori biotechnologybiotechnolog productsbiopharmaceuticalspharmaceut industrylif scienc industryspecialti drugspharmaci  